Athernal Bio Secures £3.5Million Funding

The company has raised £3.5M in funding, led by Delin Ventures, to advance its innovative treatments and accelerate research and development in the hematology and immunotherapy space.

The company plans to use the funds to advance in vivo proof-of-concept studies for CH treatment, preparing for an IND targeting this underserved patient population.

Read Also - Katana Secures €14M Series B Round Extension Funding

Founded by Nirupa Desai, MD, PhD, and Ieuan Walker, MD, and incubated by Delin, Athernal Bio led by CEO Colin Freund is developing targeted immunotherapies to treat blood cancer precursor conditions. The company focuses on high-risk clonal haematopoiesis (CH), a common precursor that can progress to acute myeloid leukaemia and other blood cancers.

Nirupa Desai, Co-founder and Chief Scientific Officer of Athernal Bio said: CH is a well-recognised precursor to blood cancer, but no targeted treatment options currently exist. Patients can often live for years under the weight of knowing their condition could progress to AML, without any way to intervene.

The company has assembled a strong team, backed by esteemed advisors across the US and Europe, to accelerate the development of the first therapeutic options for early intervention in high-risk CH, aiming to prevent cancer before it develops.

About Athernal Bio

Athernal Bio develops targeted immunotherapies to treat high-risk clonal haematopoiesis (CH) a precursor to blood cancers. By addressing CH early, the company aims to intervene before cancers develop offering patients preventative treatment and transforming outcomes in hematological oncology.